Metilfenidato Sandoz (Methylphenidate Hydrochloride)

Metilfenidato Sandoz is a central nervous system stimulant used in the treatment of neurobehavioral disorders.

• Attention deficit hyperactivity disorder (ADHD) in children: improves concentration, reduces hyperactivity and impulsivity.
• Attention deficit hyperactivity disorder (ADHD) in adults: enhances focus and decreases distractibility.
• Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.

• Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their transporters in neuronal synapses. This increases the extracellular concentrations of these catecholamines, enhancing neurotransmission in brain regions that regulate attention, impulse control, and arousal, thereby producing its therapeutic effects in ADHD and narcolepsy.

Methylphenidate may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

• Insomnia: difficulty falling or staying asleep.
• Decreased appetite: reduced desire for food, possibly leading to weight loss.
• Headache: mild to moderate pain in the head region.
• Stomach upset: nausea, abdominal discomfort or dyspepsia.

Serious or Rare Side Effects

• Cardiovascular events: hypertension, tachycardia, or other heart‑related complications.
• Psychosis or mania: emergence of hallucinations, delusions, or elevated mood.
• Severe allergic reaction: anaphylaxis, angioedema, or skin rash requiring urgent medical care.

Before prescribing methylphenidate, clinicians should consider several safety measures.

• Cardiovascular assessment: evaluate blood pressure and cardiac history prior to initiation.
• Psychiatric monitoring: watch for emergence of psychosis, mania, or mood swings.
• Growth monitoring in children: regularly track height and weight during therapy.
• Potential for abuse: prescribe only when benefits outweigh risk of dependence.
• Drug interactions: review concomitant medications, especially MAO inhibitors and antihypertensives.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Methylphenidate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Tricyclic antidepressants: may increase cardiovascular stimulation.

Moderate Interactions (Monitor Closely)

• Antihypertensives: methylphenidate may reduce their efficacy.
• Anticonvulsants (e.g., carbamazepine): may lower methylphenidate plasma levels.
• CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate concentrations.